The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

34
[1] The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back 17th January 2014, QMRI, University of Edinburgh Christopher Southan, IUPHAR Database and Guide to PHARMACOLOGY Web Portal Group, Queen's Medical Research Institute, University of Edinburgh, UK http://www.guidetopharmacology.org/ [email protected] Orchid ID 0000-0001-9580-0446 Twitter: http://twitter.com/#!/cdsouthan Blog: http://cdsouthan.blogspot.com/ LinkedIN: http://www.linkedin.com/in/cdsouthan Presentations: http://www.slideshare.net/cdsouthan http:// cdsouthan.blogspot.se/2014/01/a-tale-of-two-targets-bace1-and-bace2.ht ml

description

Slides presented at the University of Edinburgh in Jan 2014, based on our paper "A tale of two drug targets: the evolutionary history of BACE1 and BACE2" http://www.ncbi.nlm.nih.gov/pubmed/24381583 The beta amyloid (APP) cleaving enzyme (BACE1) has been a drug target for Alzheimer's Disease (AD) since 1999 with lead inhibitors now entering clinical trials. In 2011, the paralog, BACE2, became a new target for type II diabetes (T2DM) having been identified as a TMEM27 secretase regulating pancreatic β cell function. However, the normal roles of both enzymes are unclear. This study outlines their evolutionary history and new opportunities for functional genomics. We identified 30 homologs (UrBACEs) in basal phyla including Placozoans, Cnidarians, Choanoflagellates, Porifera, Echinoderms, Annelids, Mollusks and Ascidians (but not Ecdysozoans). UrBACEs are predominantly single copy, show 35–45% protein sequence identity with mammalian BACE1, are ~100 residues longer than cathepsin paralogs with an aspartyl protease domain flanked by a signal peptide and a C-terminal transmembrane domain. While multiple paralogs in Trichoplax and Monosiga pre-date the nervous system, duplication of the UrBACE in fish gave rise to BACE1 and BACE2 in the vertebrate lineage. The latter evolved more rapidly as the former maintained the emergent neuronal role. In mammals, Ka/Ks for BACE2 is higher than BACE1 but low ratios for both suggest purifying selection. The 5' exons show higher Ka/Ks than the catalytic section. Model organism genomes show the absence of certain BACE human substrates when the UrBACE is present. Experiments could thus reveal undiscovered substrates and roles. The human protease double-target status means that evolutionary trajectories and functional shifts associated with different substrates will have implications for the development of clinical candidates for both AD and T2DM. A rational basis for inhibition specificity ratios and assessing target-related side effects will be facilitated by a more complete picture of BACE1 and BACE2 functions informed by their evolutionary context.

Transcript of The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

Page 1: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[1]

The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

17th January 2014, QMRI, University of Edinburgh

Christopher Southan, IUPHAR Database and Guide to PHARMACOLOGY Web Portal Group, Queen's Medical Research Institute, University of Edinburgh, UK

http://www.guidetopharmacology.org/[email protected] ID 0000-0001-9580-0446Twitter: http://twitter.com/#!/cdsouthanBlog: http://cdsouthan.blogspot.com/LinkedIN: http://www.linkedin.com/in/cdsouthan Presentations: http://www.slideshare.net/cdsouthan

http://cdsouthan.blogspot.se/2014/01/a-tale-of-two-targets-bace1-and-bace2.html

Page 2: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[2]

Reference and Acknowledgment

PMID:24381583 (2013)

Page 3: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[3]

Presentation Outline

• Introducing the BACE1 and BACE2 Aspartyl proteases• BACE1 as an Alzheimer’s disease (AD) target• BACE2 as a Type II Diabetes (T2D) target• Drug discovery > evolution - the three paralogs• The chordate/vetebrate BACE1/2 evolutionary trajectory• The ancestral UrBACE in basal animal phyla and oily tails• Where the either the UrBACE or certain substrates are missing• Corroboration by another paper • Evolution back to drug discovery – functional genomics• Evolution informs drug development

Page 4: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[4]

Starting Points

Page 5: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[5]

BACE1 Normal Function: Neuronal Pleiotropic

• Review articles collate ~13 non-amyloidogenic in vivo substrates• Suggested normal cleaved APP (P05067) ectodomain involvement nerve cells

and Aβ peptide dampening of neuronal hyperactivity• Voltage-gated sodium channel subunits (SCN4B, O60939) substrates for

regulation of Nav1 channel metabolism• Neuregulin(NRG1, Q022979) substrate for control of nerve cell myelination• Amyloid-like protein 2 (APP2, Q06481) substrate for ectodomain fragments• Pancreatic ectodomain shedding of broad set of β-cell-enriched substrates• KO-mice subtle neurochemical deficits and behavioural changes• Zebrafish KO substrates related to neurite outgrowth and axon guidance• Zebrafish KO shows peripheral hypomyelination

Page 6: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[6]

BACE2 Normal Function : Peripheral Pleiotropic

• Similar to BACE1 in catalytic activity with a large open cleft• Balance of evidence against being an APP beta secretase in vivo• Broad tissue distribution attributable to different promoter usage to BACE1• KO mice “normal” • Neonatal mortality increase in mouse double-KO (Bace1-/-; Bace2-/-) • TMM27 (Q9HBJ8) secretase in mice and in human pancreatic β-cell membranes• Pancreatic ectodomain shedding of narrow set of β-cell substrates• Processes mouse pigment cell-specific Melanocyte Protein (Q60696)• Zebrafish KO melanocyte migration phenotype. • Zebrafish Double KO (Bace1-/-; Bace2-/-) viable does not enhance the single

mutant phenotypes, indicating non-redundant functions

Page 7: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[7]

Incidence of Alzheimer's Disease (AD)(by millions vs age in USA)

Page 8: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[8]

A-beta 1-42 (sp|P05067|672-713)

Regulated Intramembrane Proteolysis (RIP): APP Secretases as AD Targets

http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4865

Page 9: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[9]

BACE1 Inhibitor Phase I (discontinued)AZD3839, Ki 26.1 nM

http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6931

Page 10: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[10]

Incidence of Type 2 Diabetes (by millions world-wide)

Page 11: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[11]

PMID:21907142 (2011)

BACE2 Target Validation: 10 years after BACE1

PMID:23506624 (2012)

http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6540

Page 12: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[12]

Global Drug

Discovery Output

for BACE1 (left) and

BACE1 (right)

Southan C, Varkonyi P, Boppana K, Jagarlapudi SA, et al. (2013) Tracking 20 Years of Compound-to-Target Output from Literature and Patents.http://www.plosone.org/article/info:doi/10.1371/journal.pone.0077142

Page 13: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[13]

Drug Discovery Output for BACE1 from UKPMC

http://cdsouthan.blogspot.se/2013/11/drug-target-time-tracking.html

Page 14: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[14]

From Drug Discovery to Evolution

PMID:12904811 (2003)

Page 15: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[15]

A Tale of three Paralogs (I)

BACE1, Chromosome 11

BACE2, Chromosome 21

CATE, Chromosome 1

50% identity

27% identity

mRNA tissue distributionProtein sequence comparison

Page 16: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[16]

BACE2

BACE1

CATE

A Tale of three Paralogs (II)

InterProScan outputs

Page 17: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[17]

Challenges in Finding Orthologs: Truncated ORFs from Genome Pipelines

Page 18: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[18]

Many Ensembl Orthologs have Errors

80 orthologs of BACE1 in Ensembl % target ID (blue) vs. % query ID

Page 19: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[19]

BACE in Chordates

Page 20: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[20]

BACE in Chordates

• Ensembl has dense vertebrate coverage so we chose spaced sampling• Amphioxus outgroup consistent with protochordate 2R whole-genome

duplication followed by paralog persistence • Distinctly accelerated evolution of BACE2 (neofunctionalisation ?)• Inferred neuronal role for BAC1 but no data outside human, mouse, fish • Long branches are partial sequences• Birds group with turtles• Coelacanth groups with reptiles and tetrapods (not ray-finned fish)• Xenopus laevis tetraploidisation has maintained “double” paralogs• No evidence for pseudogenes or “dead” variants• Implication of common origin between nerve and pancreatic cells

Page 21: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[21]

Rates of Recent Evolution

Ka/Ks vs exon position for human/mouse/rat BACE1&2

0

0.05

0.1

0.15

0.2

0.25

Exon1

Exon2

Exon3

Exon4

Exon5

Exon6

Exon7

Exon8

Exon9

Ka/

Ks BACE1

BACE2

• Ka/Ks reflects the level of purifying selection• Exon 1 is subject to weak selection while exons 4-6 are under

strong selection (catalytic site)• Ka/Ks for BACE2 is on average twice that for BACE1

Page 22: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[22]

Discovering the UrBACE: Human BACE1 vs Monosiga (Choanoflagellate)

33% identity over 432 residues, 9% gaps, divergence time ~0.8 billion years

Page 23: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[23]

Digging Deep: “BACE-like” Criteria • Reciprocal BLAST highest score usually against a BACE1• Mostly single copies (i.e. just one UrBACE)• Identity across the major part of the ORF < 35% without over-gapping• Cathepsin paralogs drop to ~ 25% identity over ~350 residues with

~20% gapping • Typically ~100 residues longer than cathepsins • N-terminal signal peptide and a C-terminal transmembrane (CTM) either

side of the protease domain • CTM is absent from cathepsin paralogs although they also have N-

terminal signal peptides • Presence of diagnostic PRINTS matches, including at least one of the

profiles for BACE, typically BACE1 • Cathepsins and BACE2 sequences consistently showed two matches to

the Prosite PS00141. UrBACEs showed only the single proximal N-terminal match.

• Iterating trees with different parameterizations, including cathepsins as out-groups, support the UrBACE grouping

Page 24: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[24]

The UrBACE Evolutionary Trajectory

• After duplication from a cathepsin ancestor the emergence of the UrBACE protein sequence is distinct

• Cathepsin paralogs form a clear outgroup • “Shuffling-in” of the CTM is the defining post-duplication shift in cellular

location and function• Multiple divergent paralogs in basal phyla (2 in Monosiga, 3 in

Trichoplax) predate the nervous system• Found in cnidaria with only nerve nets• Long branch lengths mainly due to partial sequences• Major orders now represented by draft genome assemblies• Basal relationships of Eumetazoans still unresolved• Beyond limited EST coverage no tissue distribution or functional data

Page 25: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[25]

UrBACEs and Cathepsin Paralogs

Page 26: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[26]

Oily Tails: the Key to Secretase Function

BACE1 S-palmitoylation at 4 Cys residues

BACE2

UrBACE

Page 27: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[27]

Animal Lineages with no UrBACE

Non-orthologous replacement of UrBACE for pre- or post- neuronal RIP-related secretase functions ?

Demosponge

Page 28: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[28]

Detecting BACE1 and BACE2 substrate homologs:(note UrBACE + and APP -)

BACE1 (P56817), APP (P05067), NRG1 (Q02297), SCN2B (O60939), TMEM27 (Q9HBJ8), and PSEN1 (P49768) for comparison

X represents probable absence by low BLASTP score (score matrix in supplementary data)

Page 29: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[29]

The BACE that probably isn’t (because it’s a cathepsin sequence)

Neurotoxic effects induced by the Drosophila amyloid-beta peptide suggest a conserved toxic function (PMID:19049874, 2009)• “We therefore propose that this fly enzyme represents an endogenous

fly β-secretase and now named it dBACE”

Page 30: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[30]

Independent Corroboration

Asynchronous Evolutionary Origins of Aβ and BACE1 (PMID:24361992, Dec 2013)

“sequences homologous to Aβ are not found outside gnathostomes and the β cut site is only conserved within sarcopterygians. BACE1 enzymes, however, extend through basal chordates and as far as cnidaria. We then sought to determine whether BACE1 from a species that never evolved Aβ could proteolyze APP substrates which include Aβ. We demonstrate that BACE1 from a basal chordate is a functional ortholog that can liberate Aβ from full length human APP, indicating BACE1 activity evolved at least 360 million years before Aβ”

Chinese Hamster Ovary cells transfected with human APP

Page 31: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[31]

From Evolution back to Drug Discovery

PMID:23128209

PMID:23128209

http://en.wikipedia.org/wiki/Model_organism

Page 32: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[32]

Opportunities for Functional Genomics

• UrBACE experiments to illuminate contemporary BACE roles and networks

• Comparative expression data to give clues• KO or RNAi for protease or substrate ablation• Mutants for more subtle perturbations• Chemical perturbations with BACE1 and/or BACE2 inhibitors as probes• Substitution options (e.g. swap UrBACE for human BACE1)• Omics profiling for phenotypic read-out• Smaller gene repertoires > simpler result interpretation • UrBACE –ve and APP (like) +ve organisms as important controls• Could detect UrBACE function shifts (e.g. pre and post-nervous system)• Vertebrates will also show functional shifts for BACE1 and BACE1 (e.g.

melanocyte role)

Page 33: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[33]

Evolution-informed Drug Development

• Clinical candidate inhibitors face first-in-class challenges • Reciprocal specificity screening of both paralogs (in ChEMBL_17 the

tested compound ratio for BACE1:BACE2 is 3999:563)• Specificity ratios (e.g. IC50s for BACE1:BACE2) will be chosen more

carefully and factor-in brain penetration • New substrates verified in model organisms can be assessed for human

side-effect liabilities and biomarkers• Substrate-specific inhibitor selectivity could be an option (e.g. neuregulin-

sparing)• Screen BACE1 leads in T2D models and BACE2 leads in AD models • Possible new lower organism phenotypic assays for BACE inhibitors, even

with UrBACE• Important to develop pathway perspectives on both paralogs

Page 34: The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

[34]

Questions ?(and you can try your own phylogenies at home)

http://figshare.com/articles/Supplementary_Data_for_Southan_Hancock_BACE_evolution_paper/855620